A reduction in the mortality rate of cutaneous malignant melanoma, the most lethal form of skin cancer, is on the horizon for light-skinned populations, a recent study published in the European Journal of Cancer reports.
MRV Research
Nivolumab Safer, More Effective Than Chemo for Advanced Melanoma
According to a recent study published online in the journal The Lancet Oncology, researchers have found that nivolumab led to a greater proportion of patients with advanced melanoma who progressed after anti-CTLA-4 treatment achieving an objective response and with fewer adverse events compared with investigator’s choice of chemotherapy (ICC)
Research Shows Standard Treatments Not Effective Against Nodal in Metastatic Melanoma
A recent study published in Molecular Cancer Research, led by researchers from the laboratory of Mary J.C. Hendrix, found that standard treatments to address metastatic melanoma are ineffective against Nodal, a growth factor protein. Further, this study also revealed that combination therapies that include anti-Nodal antibodies and DTIC offer a very promising alternative. Previous research projects from the Hendrix laboratory proved that Nodal is essential for human embryonic development and that it re-emerges in metastatic melanoma
Study Demonstrates New Noninvasive Gene Expression Profile Test Predicts Melanoma Risk More Accurately Than AJCC Online Predictor Tool
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today announced study results demonstrating that its DecisionDx-Melanoma™ gene expression profile (GEP) test was significantly more accurate in predicting risk of metastasis and survival in patients with cutaneous melanoma than a standard predictive method currently used to guide patient management. The data were presented during the 73rd Annual Meeting of the American Academy of Dermatology (AAD).